Diagnosis and Treatment of Traumatic Brain Injury, 2022, Pages 27-38
This book chapter advances SDG #3 and #10 by focusing on an emblematic delayed-onset pathology often seen after traumatic brain injury—Alzheimer’s disease—and explain its relationship with chronic traumatic encephalopathy.
Plant Extracts in Neurodegenerative Diseases, 2022, Pages 1-15
This book chapter advances SDG #3 and #10 by focusing on polyphenols and flavonoids and their crucial role in decreasing AD symptoms. In addition, it highlights the neuroprotective role of various essential ingredients of plant extracts such as Icariside, Onjisaponin B, Asarones, Liquiritin, Tanshinone IIA (TIIA) and cryptotanshinone (CT), Ginsenoside Rg1, and n-Butylidenephthalide. The efficacy of green nanotechnology are also discussed.
Exercise to Prevent and Manage Chronic Disease Across the Lifespan, 2022, Pages 413-421
This book chapter advances SDG #3 and #10 by outlining the pathophysiology associated with Alzheimer’s disease and provide an overview of the impact of exercise programs on cognition, physical functional abilities, behavioral, and psychological symptoms and quality of life.
Neurobiology of Brain Disorders (Second Edition), Biological Basis of Neurological and Psychiatric Disorders, 2022, Pages 313-336
This book chapter advances SDG #3 and #10 by reviewing several key topics that influence our understanding of pathogenic mechanisms and lead to the identification of novel therapeutic strategies. These include the diagnostic spectrum of MCI and AD, genetic risk alleles associated with late-onset AD, structures of gamma-secretase and tau, imaging and fluid biomarkers, the role of microglia and neuroinflammation, and novel animal models of AD.
Nanomedical Drug Delivery for Neurodegenerative Diseases, 2022, Pages 223-242
This book chapter advances SDG #3 and #10 by highlighting a few newly updated nano drug delivery technologies implemented in Alzheimer’s disease therapies and prospects for the future regarding potential molecular mechanisms of nano drug delivery methods
Nanomedical Drug Delivery for Neurodegenerative Diseases, 2022, Pages 17-39
This book chapter advances SDG #3 and #10 by presenting drug delivery systems based on nanotechnology to treat Alzheimer’s disease.
This book chapter advances SDG #3 and #10 by reviewing studies that showed treatments with multiple sessions of rTMS can influence cognition in people with neurodegenerative diseases. The chapter also considers novel therapeutic approaches based on the clinical use of rTMS.
This book chapter advances SDG 3 and 10 by presenting that (1) some of these depression scales do not correlate, suggesting that they assess different aspects of depression; (2) reports of depression in dementia vary based on depression in dementia scale used; and (3) severe memory impairment may impact the ability to assess depression in the patients using self-reports.
Human Caspases and Neuronal Apoptosis in Neurodegenerative Diseases, 2022, Pages 69-151
This book chapter advances SDG #3 and #10 by reviewing the latest developments in the field of clinical diagnosis and pharmacotherapeutics have provided hope to ameliorate the behavioral changes and cognitive disturbances associated with the disease.
This book chapter advances SDG 3 and 10 by discussing the importance of social support and psychological flexibility to act as a buffer between the effects of COVID-19 on psychological distress and mental health.
